National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer

International Journal of Gynecological Cancer

Volumn 18, Issue SUPPL. 1, 2008, Pages 26-28

  Trimble, E L ^a   Christian, M C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Clinical trials; Intraperitoneal therapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ARTICLE; CANCER CENTER; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; EDUCATION; HEALTH CARE ORGANIZATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZATION; UNITED STATES;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; NATIONAL CANCER INSTITUTE (U.S.); OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 40749153573     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01100.x     Document Type: Article

References (15)

1. Armstrong DK, Bundy B, Wenzel L et al. Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study. N Engl J Med 2006 354 : 34 43.
2. Walker JL, Armstrong D, Huang HQ et al. Intraperitoneal catheter outcomes in a phase II trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006 100 : 27 32.
3. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996 335 : 1950 5.
4. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001 19 : 1001 7.
5. Piccart MJ, Floquet A, Scarfone G et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 2003 13 (Suppl. 2 196 203.
6. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006 CD005340.
7. Kyrgiou M, Salanti G, Pavlidis N et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 2006 98 : 1655 63.
8. Available at : http://ctep.cancer.gov/highlights/ovarian.html. Accessed 4 October 2007.
9. Cannistra SA. Intraperitoneal chemotherapy comes of age. N Engl J Med 2006 354 : 77 9.
10. Trimble EL, Christian MC. Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol 2006 100 : 3 4.
11. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002 20 : 1248 59.
12. Available at : http://www.gog.org/ipchemoed/ipchemoed.html. Accessed 4 October 2007.
13. Available at : http://ctep.cancer.gov/resources/gcig/. Accessed 4 October 2007.
14. Markman M, Walker J. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 2006 24 : 988 94.
15. Fuiwara K, Armstrong D, Morgan M et al. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 2007 17 : 1 20.